Wouter Meijers

Dr. Wouter Meijers is a researcher at Erasmus MC, affiliated with the Department of Cardiology within the Erasmus School of Medicine. His work focuses on the pathophysiology of heart failure, with a strong emphasis on biomarkers, systemic inflammation, oxidative stress, and the gut-heart axis. He is actively involved in clinical and translational research, contributing to major studies on heart failure mechanisms and Long-COVID cardiovascular complications.

His research interests include:

• Congestive heart failure
• Biomarkers such as galectin-3 and peroxiredoxin-4
• Oxidative stress and mitochondrial dysfunction
• Cardiac fibrosis and remodeling
• Gut microbiome and metabolic alterations in heart disease
• Cardiotoxicity beyond cardiomyocytes
• Epigenetics of cardiomyopathies

Dr. Meijers' recent publications highlight a strong trend toward understanding systemic contributors to heart failure, including gut-derived metabolites, inflammatory pathways, and oxidative stress markers. His work often involves large cohort studies and collaborative international research, particularly in the areas of heart failure with preserved ejection fraction, Long-COVID cardiovascular impact, and novel biomarker discovery.

While no specific awards are listed in the provided text, his research has garnered attention in social and academic networks, including mentions on X (formerly Twitter), Bluesky, and Mendeley. His publications appear in high-impact journals such as the European Journal of Heart Failure, International Journal of Cardiology, and Heart Lung and Circulation.

Dr. Meijers collaborates extensively with leading cardiologists and researchers at Erasmus MC, including Prof. R.A. de Boer and others in the cardiology and genetics departments. Although no direct mention of student supervision is found, his role in multi-center trials and mechanistic studies suggests involvement in training and mentorship within the research team.

He is part of a dynamic research environment focused on advancing the understanding of heart failure through integrative approaches combining clinical data, molecular biology, and systems-level analysis. His work contributes to the development of novel diagnostic and therapeutic strategies for cardiovascular disease.